We were the first international law firm to establish a stand-alone, comprehensive food and drug regulatory practice in China. Since 2007, we have witnessed the drastic changes in China’s regulatory system and how those changes have impacted the life sciences industry on a regional level. During this time, our lawyers have helped clients navigate the ever-changing regulatory environment of the life sciences market.
Sidley was honored with a memorandum of understanding issued by the China Center for Pharmaceutical International Exchange, an institution affiliated with the National Medical Products Administration, previously the China Food and Drug Administration, and by the Shanghai Institute for Food and Drug Safety, under which we provide input into new drug, device, food, and cosmetics laws and regulations.
We bring value to our life sciences clients in the following ways:
- Industry Knowledge: Our skills and experience cover all areas of the life sciences industry
- Acute Market Awareness: We are at the forefront of new industry developments, with a focus on structuring and negotiating market-leading terms
- Proven Track Record: We are the only firm to receive a Band 1 ranking in life sciences for 13 consecutive years by Chambers Asia Pacific/Greater China Region (2010–2022)
- Commitment to China: Our team brings international industry insight to each project in China, developing benchmarks and best practices to drive innovation
- Enduring Client Relationships: We believe that our global resources and commitment to providing quality service have led to long-standing relationships with our clients
- Dedicated Team: We provide direct access to dedicated client teams, ensuring our clients are given the best customized service
“They have extremely rich experience in advising the life sciences industry and also the most cutting-edge knowledge on the development of China’s life sciences industry.”
Chambers Greater China Region 2022
Full-Service Life Sciences Capabilities in China
Our lawyers are active across all areas of the life sciences industry in China, including:
|
Regulatory
|
Transactional
|
Compliance and Enforcement
|
Dispute Resolution
|
- Drugs
- Digital health
- Vaccines/biologicals
- Medical devices
- Novel therapies
- Food/cosmetics
- Animal health
- Crop sciences
- Product approval strategies
- Clinical studies
- Commercialization
- Safety vigilance
|
- Capital markets
- Private equity
- Venture capital
- M&A
- Joint ventures
- Collaboration
- Licensing
|
- Anti-counterfeiting
- Anti-bribery/Foreign Corrupt Practices Act
- Antitrust
- GxP (good manufacturing practices (GMP), good clinical practices (GCP), and good laboratory practices (GLP)) and quality system regulations
- Data protection and privacy
|
- International arbitration
|
China Life Sciences Roundtable
We have been hosting our semi-annual event — Sidley’s China Life Sciences Roundtable — for 13 years. The series, held in Beijing and Shanghai, provides an intimate setting for lawyers and compliance officers to engage in an interactive dialogue on timely topics. If you would like to know more about the event, please email sidleychinalifesciencesroundtable@sidley.com.
“They understand very well the historical evolution of various critical regulatory topics and their complex context, which means their legal advice goes beyond the interpretation of laws and is rather a comprehensive guidance to our business.”
Chambers Greater China Region 2022
